- Home
- HBAN vs PODD Comparison
HBAN vs PODD Comparison
Compare HBAN & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- PODD
- Stock Information
- Founded
- HBAN 1866
- PODD 2000
- Country
- HBAN United States
- PODD United States
- Employees
- HBAN N/A
- PODD N/A
- Industry
- HBAN Major Banks
- PODD Medical/Dental Instruments
- Sector
- HBAN Finance
- PODD Health Care
- Exchange
- HBAN Nasdaq
- PODD Nasdaq
- Market Cap
- HBAN 21.2B
- PODD 17.2B
- IPO Year
- HBAN N/A
- PODD 2007
- Fundamental
- Price
- HBAN $15.22
- PODD $257.00
- Analyst Decision
- HBAN Buy
- PODD Buy
- Analyst Count
- HBAN 21
- PODD 17
- Target Price
- HBAN $17.50
- PODD $302.56
- AVG Volume (30 Days)
- HBAN 19.3M
- PODD 695.5K
- Earning Date
- HBAN 04-17-2025
- PODD 05-08-2025
- Dividend Yield
- HBAN 4.07%
- PODD N/A
- EPS Growth
- HBAN 17.13
- PODD 96.55
- EPS
- HBAN 1.30
- PODD 5.78
- Revenue
- HBAN $7,104,000,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- HBAN $16.25
- PODD $20.53
- Revenue Next Year
- HBAN $5.04
- PODD $17.42
- P/E Ratio
- HBAN $11.72
- PODD $44.43
- Revenue Growth
- HBAN 5.17
- PODD 22.07
- 52 Week Low
- HBAN $11.92
- PODD $160.19
- 52 Week High
- HBAN $18.45
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- HBAN 61.29
- PODD 50.41
- Support Level
- HBAN $14.79
- PODD $252.88
- Resistance Level
- HBAN $15.25
- PODD $260.96
- Average True Range (ATR)
- HBAN 0.33
- PODD 7.68
- MACD
- HBAN 0.16
- PODD 1.34
- Stochastic Oscillator
- HBAN 93.47
- PODD 65.40
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $200 billion in assets (as of 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.